Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low-Dose IL-2 in the Treatment of Lupus.

Literature DB >> 27734211

Low-Dose IL-2 in the Treatment of Lupus.

Abstract

Recent extensive research on interleukin-2 (IL-2)/IL-2 receptor (IL-2R) biology has revealed its critical role in the regulation of immune tolerance by influencing regulatory T (Treg) cell functions and survival. Since in vivo low-dose IL-2 administration in humans has been confirmed to be safe and effective in expanding Treg, it is likely that it may be considered for the treatment of several autoimmune diseases including systemic lupus erythematousus (SLE). A recent clinical trial demonstrated the safety and efficacy of low-dose IL-2 treatment on SLE. In SLE, T cells show aberrant function such as deficient IL-2 production and abnormal signaling events. Expansion of Treg by IL-2 represents a specific strategy to control self-tolerance; however, restoration of abnormal immune function and responses should be addressed more carefully in patients with SLE considering the complexity of disease etiology and pathogenesis.

Entities: Chemical

Keywords: Interleukin-2; Systemic lupus erythematosus; low-dose IL-2 treatment; regulatory T cells

Mesh：

Substances：
Interleukin-2

Year: 2016 PMID： 27734211 DOI： 10.1007/s11926-016-0617-5

Source DB: PubMed Journal: Curr Rheumatol Rep ISSN： 1523-3774 Impact factor: 4.686

57 in total

Review 1. Systemic lupus erythematosus.

Authors: George C Tsokos
Journal: N Engl J Med Date: 2011-12-01 Impact factor: 91.245

2. IL-2 requirement for human plasma cell generation: coupling differentiation and proliferation by enhancing MAPK-ERK signaling.

Authors: Simon Le Gallou; Gersende Caron; Céline Delaloy; Delphine Rossille; Karin Tarte; Thierry Fest
Journal: J Immunol Date: 2012-05-25 Impact factor: 5.422

Review 3. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.

Authors: Vaishali R Moulton; George C Tsokos
Journal: J Clin Invest Date: 2015-05-11 Impact factor: 14.808

4. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity.

Authors: Daniel R Neill; See Heng Wong; Agustin Bellosi; Robin J Flynn; Maria Daly; Theresa K A Langford; Christine Bucks; Colleen M Kane; Padraic G Fallon; Richard Pannell; Helen E Jolin; Andrew N J McKenzie
Journal: Nature Date: 2010-03-03 Impact factor: 49.962

5. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.

Authors: Ken-ichi Matsuoka; John Koreth; Haesook T Kim; Gregory Bascug; Sean McDonough; Yutaka Kawano; Kazuyuki Murase; Corey Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal: Sci Transl Med Date: 2013-04-03 Impact factor: 17.956

6. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.

Authors: Arian Laurence; Cristina M Tato; Todd S Davidson; Yuka Kanno; Zhi Chen; Zhengju Yao; Rebecca B Blank; Françoise Meylan; Richard Siegel; Lothar Hennighausen; Ethan M Shevach; John J O'shea
Journal: Immunity Date: 2007-03 Impact factor: 31.745

7. Protein phosphatase 2A activity is required for functional adherent junctions in endothelial cells.

Authors: Anita Kása; István Czikora; Alexander D Verin; Pál Gergely; Csilla Csortos
Journal: Microvasc Res Date: 2013-05-28 Impact factor: 3.514

8. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.

Authors: Jason Park; Stephen H Wrzesinski; Eric Stern; Michael Look; Jason Criscione; Ragy Ragheb; Steven M Jay; Stacey L Demento; Atu Agawu; Paula Licona Limon; Anthony F Ferrandino; David Gonzalez; Ann Habermann; Richard A Flavell; Tarek M Fahmy
Journal: Nat Mater Date: 2012-07-15 Impact factor: 43.841

9. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

Authors: John Koreth; Haesook T Kim; Kyle T Jones; Paulina B Lange; Carol G Reynolds; Marie J Chammas; Katherine Dusenbury; Jennifer Whangbo; Sarah Nikiforow; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Yi-Bin Chen; David Avigan; Bruce R Blazar; Joseph H Antin; Jerome Ritz; Robert J Soiffer
Journal: Blood Date: 2016-04-12 Impact factor: 22.113

10. Autophagy is required for IL-2-mediated fibroblast growth.

Authors: Rui Kang; Daolin Tang; Michael T Lotze; Herbert J Zeh Iii
Journal: Exp Cell Res Date: 2012-11-27 Impact factor: 3.905

17 in total

1. IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent.

Authors: Marta E Stremska; Chao Dai; Rajkumar Venkatadri; Hongyang Wang; Vikram Sabapathy; Gaurav Kumar; Sheethal Jose; Saleh Mohammad; Sun-Sang J Sung; Shu Man Fu; Rahul Sharma
Journal: J Autoimmun Date: 2019-05-15 Impact factor: 7.094

Review 2. The role of FOXP3⁺ regulatory T cells in human autoimmune and inflammatory diseases.

Authors: A Mohr; M Atif; R Balderas; G Gorochov; M Miyara
Journal: Clin Exp Immunol Date: 2019-03-24 Impact factor: 4.330

Review 3. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.

Authors: Vaishali R Moulton; Abel Suarez-Fueyo; Esra Meidan; Hao Li; Masayuki Mizui; George C Tsokos
Journal: Trends Mol Med Date: 2017-06-13 Impact factor: 11.951

Review 4. T cells and autoimmune kidney disease.

Authors: Abel Suárez-Fueyo; Sean J Bradley; David Klatzmann; George C Tsokos
Journal: Nat Rev Nephrol Date: 2017-03-13 Impact factor: 28.314

5. New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.

Authors: Iñaki Sanz
Journal: Arthritis Rheumatol Date: 2017-06-16 Impact factor: 10.995

6. IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus.

Authors: Hong Dai; Fan He; George C Tsokos; Vasileios C Kyttaris
Journal: J Immunol Date: 2017-06-23 Impact factor: 5.422

7. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells.

Authors: Bo Zhang; Jiaqi Sun; Yan Wang; Dezhong Ji; Yeshuang Yuan; Shengjie Li; Yeting Sun; Yingqin Hou; Pengchong Li; Lidan Zhao; Fei Yu; Wenxiao Ma; Boyang Cheng; Ling Wu; Jin Hu; Min Wang; Wei Song; Xiaogang Li; Hao Li; Yunyun Fei; Hua Chen; Lihe Zhang; George C Tsokos; Demin Zhou; Xuan Zhang
Journal: Nat Biomed Eng Date: 2021-09-27 Impact factor: 25.671

Low-Dose IL-2 in the Treatment of Lupus.

Review 1. Systemic lupus erythematosus.

2. IL-2 requirement for human plasma cell generation: coupling differentiation and proliferation by enhancing MAPK-ERK signaling.

Review 3. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.

4. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity.

5. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.

6. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.

7. Protein phosphatase 2A activity is required for functional adherent junctions in endothelial cells.

8. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.

9. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

10. Autophagy is required for IL-2-mediated fibroblast growth.

1. IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent.

Review 2. The role of FOXP3⁺ regulatory T cells in human autoimmune and inflammatory diseases.

Review 3. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.

Review 4. T cells and autoimmune kidney disease.

5. New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.

6. IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus.

7. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells.

8. Bacteriolytic Activity Of Human Interleukin-2, Chicken Egg Lysozyme In The Presence Of Potential Effectors.

Review 9. Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells.

Review 10. Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.

Review 1. Systemic lupus erythematosus.

Review 3. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.

Review 2. The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases.

Review 3. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.

Review 4. T cells and autoimmune kidney disease.

Review 9. Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells.

Review 10. Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.

Review 2. The role of FOXP3⁺ regulatory T cells in human autoimmune and inflammatory diseases.